Illumina Cuts Forecasts As Consumer Tests, Genomics Initiatives Lag

About this time last year, DNA sequencing giant Illumina upped its financial projections, estimating its sales would grow 20 percent year-over-year. It exceeded that goal, with revenue rising 21 percent to $3.33 billion by the end of 2018. It?s a different financial story this summer. On Monday, Illumina (NASDAQ: ILMN) informed the markets that it [?]